Cipla (CIPLA) Q4 17/18 earnings summary

Executive summary

• FY18 revenue grew 6% on a GST-adjusted basis; EBITDA margin expanded 165 bps to 18.6%, and PAT rose 40% to ₹1,411 crore.

• Growth was led by India, South Africa, API and Sub-Saharan Africa; US growth remained moderate amid price erosion, delayed launches and supply disruptions.

• FY18 priorities centered on consolidation, cost containment and stronger margins; FY19 plans target growth in key markets, a deeper US portfolio and continued R&D investment.

Financial highlights

• Consolidated operating revenue was ₹15,219 crore, up 4% reported and 6% adjusted for GST; EBITDA was ₹2,826 crore, up 14.2%, with an 18.6% margin.

• Consolidated PAT was ₹1,411 crore, up 40% YoY; diluted EPS was ₹17.50 versus ₹12.50 in FY17.

• Revenue from operations was ₹15,219 crore; the FY18/FY17 reported comparison is affected by GST implementation from July 2017.

• EBITDA margin improved 165 bps on top-line growth, favorable product and geography mix, procurement and manufacturing cost controls, and Project Eagle efficiencies.

• Finance costs declined 28% to ₹114 crore, while employee expenses rose 2% to ₹2,690 crore and other expenses declined 1.4% to ₹4,264 crore.

Outlook and guidance

• FY19 priorities include India revenue of $1 billion, EBITDA margin expansion over FY18, R&D investment of 7–8%, and 20+ planned ANDA filings.

• US plans include differentiated launches, a value-focused portfolio and one limited-competition launch per quarter; recorded sales may be marginally affected by SKU rationalization.

• R&D plans call for 20+ filings and continued development of specialty and respiratory assets; respiratory’s share of R&D investment is planned to rise above 30% from 12% in FY18.

• Growth priorities include India and South Africa, expansion into China and Brazil, emerging-market partnerships, biosimilars and operating efficiencies through Project Eagle and analytics.